Apotex v. Troy
Executive Summary
FDA Chief Counsel Daniel Troy will argue the agency's case in Apotex v. HHS in federal appeals court Feb. 4. Apotex is appealing a February 2002 D.C. federal court decision that GlaxoSmithKline's late-listed patents for Paxil (paroxetine) should remain in FDA's "Orange Book." A trial on the validity of GSK's hemihydrate patent, which expires in 2006, is scheduled to begin in Chicago federal court Feb. 5...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.